10-Q/A: Xencor Restates Financials Due to Accounting Errors, Identifies Material Weaknesses in Internal Controls

Xencor's Q1 2024 financials are restated due to errors in royalty accounting, R&D expense capitalization, and state tax obligations, leading to the identification of material weaknesses in internal controls.

Summary

• Xencor has restated its previously issued financial statements for the year ended December 31, 2023, and the three months ended March 31, 2024.
• The restatement corrects errors related to the accounting treatment of a royalty transaction with OMERS Life Sciences, the unrecorded tax benefit related to research and development expenses, and an understatement of state tax obligations.
• The impact on the consolidated balance sheet as of March 31, 2024, included an understatement of accounts receivable by $12.6 million, an overstatement of deferred income by $147.5 million, an understatement of debt by $164.7 million, and an overstatement of stockholders' equity by $4.6 million.
• The impact on the consolidated statement of income (loss) for the three months ended March 31, 2024, included an understatement of revenue by $3.2 million and an understatement of interest expense by $8.6 million.
• The impact on the consolidated statement of cash flows for the three months ended March 31, 2024, included an understatement of cash flow used by operating activities by $1.6 million and an understatement of cash flow provided by financing activities by the same amount.
• The company also identified an uncertain tax position of $6.2 million owed for the fiscal year ended December 31, 2023, related to the treatment of research and development expenses under Section 174 of the Code.
• Additionally, the company understated its state income tax expense by approximately $2.1 million, net of federal benefit, for the year ended December 31, 2023.
• As a result of the restatement, management has re-evaluated the effectiveness of the company's internal controls over financial reporting as of March 31, 2024, and concluded that additional material weaknesses exist.
• Management plans to implement a more rigorous analysis of non-routine transactions, improve the process for identifying and selecting qualified third-party advisors, enhance the review of capabilities and work performed by third-party advisors, and review income tax legislative changes quarterly with a tax expert.

Sentiment

Score: 3

Explanation: The sentiment is negative due to the restatement of financials and the identification of material weaknesses in internal controls, despite the company's plans for remediation and future funding outlook.

Positives

• Management is implementing a plan to remediate the identified material weaknesses in internal control over financial reporting.
• The company is taking steps to improve its accounting processes and controls, including engaging qualified third-party advisors and enhancing the review of their work.
• The company is committed to maintaining an effective internal control environment and addressing the identified material weaknesses in a timely manner.

Negatives

• The restatement of previously issued financial statements indicates errors in the company's accounting practices.
• The identification of material weaknesses in internal control over financial reporting raises concerns about the reliability of the company's financial reporting.
• The errors required the company to restate financials and for RSM to withdraw their audit report.

Risks

• Failure to remediate the material weaknesses in internal control over financial reporting could result in further misstatements of financial statements and a failure to meet reporting obligations.
• The company may not be able to identify all material weaknesses in its internal control over financial reporting, or may experience additional material weaknesses in the future.
• The restatement and related issues could lead to a decline in investor confidence and the price of the company's common stock.

Future Outlook

Based on the current operating plan, Xencor expects that its existing cash, cash equivalents, marketable securities, and certain potential milestone payments will fund its operating expenses and capital expenditure requirements into 2027.

Industry Context

Xencor operates in the competitive biopharmaceutical industry, where companies are focused on discovering and developing engineered antibody therapeutics. The company's XmAb technology platform and drug candidates are aimed at treating cancer and other serious diseases with unmet medical needs. The company's partnerships and collaborations with other companies in the industry are a key part of its business strategy.

Comparison to Industry Standards

• It is difficult to compare Xencor's results directly to industry standards without knowing the specific details of their collaborations and licensing agreements.
• However, the restatement of financial statements and identification of material weaknesses in internal controls are concerning and could negatively impact investor confidence.
• Other companies in the biopharmaceutical industry, such as Amgen, Regeneron, and Gilead, have robust internal control systems and are committed to accurate financial reporting.
• Xencor will need to demonstrate that it is taking the necessary steps to remediate the identified weaknesses and improve its financial reporting processes.

Stakeholder Impact

• Shareholders may experience a decline in the value of their investment due to the restatement and identified material weaknesses.
• Employees may be affected by the changes in internal controls and processes.
• Partners may need to reassess their relationships with Xencor due to the financial reporting issues.
• Creditors may be concerned about the company's ability to meet its financial obligations.

Next Steps

• Management plans to implement a more rigorous analysis of non-routine transactions.
• The company will improve its process to identify and select qualified third-party advisors.
• Xencor will enhance its review of capabilities and work performed by the third-party advisors.
• The company will review income tax legislative changes and their impact to financial statements with a tax expert on a quarterly basis.

Key Dates

Keywords

restatement, internal controls, material weakness, financial reporting, royalty accounting, research and development expenses, tax obligations, OMERS Life Sciences, Ultomiris, Xencor